Dual defense: Opportunities and challenges of GLP-1 receptor agonists in reducing dementia risk in type 2 diabetes!
作者信息
Adnan Saman, Qureshi Muniza, Arif Sania, Fatima Kinza
机构信息
Department of health sciences, Ziauddin University, Karachi, Pakistan.
出版信息
Alzheimers Dement. 2025 May;21(5):e70336. doi: 10.1002/alz.70336.
Abstract
摘要
相似文献
1
Dual defense: Opportunities and challenges of GLP-1 receptor agonists in reducing dementia risk in type 2 diabetes!双重防御：胰高血糖素样肽-1受体激动剂在降低2型糖尿病患者痴呆风险中的机遇与挑战！
Alzheimers Dement. 2025 May;21(5):e70336. doi: 10.1002/alz.70336.
2
Comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in preventing Alzheimer's disease, vascular dementia, and other dementia types among patients with type 2 diabetes.钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂在预防2型糖尿病患者患阿尔茨海默病、血管性痴呆及其他类型痴呆方面的比较疗效。
Diabetes Metab. 2025 Mar;51(2):101623. doi: 10.1016/j.diabet.2025.101623. Epub 2025 Feb 12.
3
The Effects of Dual GLP-1/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis.不同受体选择性的双重GLP-1/胰高血糖素受体激动剂在肥胖和非酒精性脂肪性肝炎小鼠模型中的作用
J Pharmacol Exp Ther. 2023 Mar;384(3):406-416. doi: 10.1124/jpet.122.001440. Epub 2022 Nov 23.
4
Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges.肠促胰素多重激动剂治疗 2 型糖尿病和肥胖症：进展与挑战。
J Endocrinol. 2024 Jul 22;262(3). doi: 10.1530/JOE-23-0404. Print 2024 Sep 1.
5
Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.药物治疗 2 型糖尿病的获益与危害：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2023 Apr 6;381:e074068. doi: 10.1136/bmj-2022-074068.
6
GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes.GLP-1 受体激动剂对 2 型糖尿病及非 2 型糖尿病患者认知功能的影响。
Diabetes Metab. 2023 Sep;49(5):101470. doi: 10.1016/j.diabet.2023.101470. Epub 2023 Aug 30.
7
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者：临床实践指南。
BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.
8
Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes.双重 GIP/GLP-1 受体激动剂：治疗 2 型糖尿病的新进展。
Ann Endocrinol (Paris). 2023 Apr;84(2):316-321. doi: 10.1016/j.ando.2022.12.423. Epub 2023 Jan 10.
9
Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.胰高血糖素样肽-1受体激动剂与甘精胰岛素治疗2型糖尿病的疗效比较：一项随机对照试验的系统评价和荟萃分析
Curr Ther Res Clin Exp. 2010 Aug;71(4):211-38. doi: 10.1016/j.curtheres.2010.08.003.
10
Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis.2型糖尿病治疗效果的年龄和性别差异：一项网状Meta分析
JAMA. 2025 Mar 25;333(12):1062-1073. doi: 10.1001/jama.2024.27402.
本文引用的文献
1
Glycated hemoglobin and body mass index as mediators of GLP-1RAs and Alzheimer's disease and related dementias in patients with type 2 diabetes.糖化血红蛋白和体重指数作为2型糖尿病患者中胰高血糖素样肽-1受体激动剂与阿尔茨海默病及相关痴呆症之间的中介因素
Alzheimers Dement. 2025 Apr;21(4):e70161. doi: 10.1002/alz.70161.
2
Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis.具有心脏保护作用的降糖药物与痴呆风险：一项系统评价和荟萃分析
JAMA Neurol. 2025 May 1;82(5):450-460. doi: 10.1001/jamaneurol.2025.0360.
3
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.胰高血糖素样肽-1 受体：作用机制与治疗进展。
Signal Transduct Target Ther. 2024 Sep 18;9(1):234. doi: 10.1038/s41392-024-01931-z.
4
Advancing dementia care in Pakistan: challenges and the way forward.推进巴基斯坦的痴呆症护理：挑战与未来之路。
Front Dement. 2023 Sep 14;2:1241927. doi: 10.3389/frdem.2023.1241927. eCollection 2023.
5
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.GLP-1 类药物治疗 2 型糖尿病和肥胖症的疗效和安全性。
Diabetes Care. 2024 Nov 1;47(11):1873-1888. doi: 10.2337/dci24-0003.
6
Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.GLP-1 受体激动剂相关的精神不良事件：基于 FDA 不良事件报告系统数据库的真实世界药物警戒研究。
Front Endocrinol (Lausanne). 2024 Feb 6;15:1330936. doi: 10.3389/fendo.2024.1330936. eCollection 2024.
7
Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.胰高血糖素样肽-1受体激动剂治疗与痴呆症发病率：来自汇总双盲随机对照试验及全国性疾病与处方登记处的数据
Alzheimers Dement (N Y). 2022 Feb 23;8(1):e12268. doi: 10.1002/trc2.12268. eCollection 2022.
8
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019.2019 年全球痴呆症患病率估计及 2050 年预测患病率：2019 年全球疾病负担研究分析。
Lancet Public Health. 2022 Feb;7(2):e105-e125. doi: 10.1016/S2468-2667(21)00249-8. Epub 2022 Jan 6.
9
Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies.糖尿病与痴呆风险：前瞻性观察研究的荟萃分析。
J Diabetes Investig. 2013 Nov 27;4(6):640-50. doi: 10.1111/jdi.12087. Epub 2013 Apr 26.
Zotero 插件